Phase 2 N=2 A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors
Keratocystic Odontogenic Tumor
Primary: KCOT Volume (Greatest Dimension) — 3; 3.8; 0; 2.6 centimeter
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
N/A N=62 Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Phase 2 N=1 Vismodegib for Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Mohs Micrographic Surgery (MMS) — 1 mm
Phase 4 N=40 Comparison of Excision Versus Punch Incision in the Treatment of Epidermal Cysts
Epidermal Cyst
Primary: Number of Participants With Cyst Recurrence — 3; 2 participants
Phase 2 N=41 To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
Basal Cell Nevus Syndrome · Gorlin Syndrome
Primary: Number of New Surgically Eligible Basal-cell Carcinomas — 34; 2 events per patient year
N/A N=180 Morphological Pattern of the Atrophic Posterior Maxillae
Bone Deficiency, Posterior Maxillae
Primary: Lateral Wall Thickness — 161 mm
N/A N=183 Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
Giant Cell Tumors
Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants
N/A N=93 Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia
Oral Epithelial Dysplasia, Mild or Moderate Grade
Primary: The Number of Participants With Both Clinical and Histological Evidence of Malignant Transformation of Oral Epithelial Dysplasia — 32; 46 participants
Phase 2 N=18 A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients
Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients
Primary: Percentage of BCCs With Complete and at Least Partial Clinical Clearance — 92; 7; 83; 77 Percentage of BCCs
Phase 2 N=28 Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Basal Cell Carcinoma
Primary: Efficacy of Vismodegib — 2; 5; 1; 1 tumors
Phase 2 N=20 GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Neoplasms, Oral · Mouth Neoplasms
Primary: Number of Participants With Changes in Putative Tumor Initiating Cell Populations as Defined by Cell Surface CD44 and Intracellular Phospho-ERK1/2 Staining After…
Early Phase 1 N=15 Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
Basal Cell Carcinoma of the Skin · Recurrent Skin Cancer
Primary: Percent Change in Surgical Defect Area After the Treatment Period Using Calipers and Photographs Was Calculated — -26.8 percentage size change from baseline
Phase 2 N=74 A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Complete Histologic Clearance — 42.0; 16.0; 44.0 Percentage of participants — p=0.8463
N/A N=278 Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract
Recurrent Head and Neck Cancer
Primary: Disease-free Survival at 2 Years — 111 Participants
Phase 3 N=174 Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Basal Cell Nevus Syndrome
Primary: Number of New BCCs Per Participant — 2.84; 4.03 New basal cell carcinomas
N/A N=45 Assessment of Ridge Preservation Using Moldable Beta-tricalcium Phosphate Bone Grafting System
Dental Implants · Alveolar Ridge Preservation
Primary: Change in Radiographic Measurements of Ridge Dimension (Horizontal Ridge Width) — 1.26; 1.28 mm
N/A N=51 CopiOs® Pericardium Membrane for Localized Alveolar Ridge Augmentation
Alveolar Ridge Defect
Primary: Change in Horizontal Ridge Widths From Baseline to 6 Months — 2.61 mm
Phase 2 N=17 Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
Basal Cell Nevus Syndrome
Primary: Clinical Efficacy: Percent Change in Tumor Size of Treatment-targeted Surgically Eligible Basal Cell Carcinomas (SEBs) From Baseline — 51.29; 26.63; 21.82 percentage…
Phase 2 N=68 Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma
Oral Squamous Cell Carcinoma
Primary: Pathologic Response. — 25; 2; 4; 4 Participants
N/A N=44 Ridge Preservation Following Tooth Extraction Using Porcine and Bovine Xenograft Materials
Alveolar Bone Loss
Primary: % Vital Bone Formation (Histological) — 31.27; 36.21 % vital bone
N/A N=66 Histological Evaluation of Healing Following Ridge Preservation Using a Combined Cortical/Cancellous Mineralized Freeze-Dried Bone Allograft
Alveolar Bone Loss
Primary: % Vital Bone Formation (Histological) — 26.4; 24.5; 28.8 percentage of total area
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=24 Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Locally Advanced Basal Cell Carcinoma · Skin Cancer · Cutaneous Malignancy
Primary: Percentage of Patients With Local-regional Control Rate — 100 percentage
N/A N=234 Intraoperative Cone-beam CT for Percutaneous Nephrolithotomy
Nephrolithiasis
Primary: "Second Look" Rate — 4; 56; 56; 118 Participants — p=<0.01
N/A N=40 Ridge Preservation After Tooth Extraction Using Cortical Versus Cancellous Freeze Dried Bone Allograft
Tooth Extraction
Primary: Histologic Percentage of Vital Bone Formation — 12.98; 16.08 percentage of vital bone
Phase 4 N=41 EMD and/or Bone Substitute for the Treatment of Class II Furcations
Periodontal Disease
Primary: Relative Horizontal Clinical Attachment Level (RHCAL) at 12 Months — 2.31; 3.00; 2.57 mm
Phase 3 N=745 Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Tear Production — 16.6; 9.2 Percentage of eyes
N/A N=39 Healing Dynamics in Human Extraction Sockets Grafted With Bio-Oss Collagen®
Tooth Loss
Primary: Number of Participants That Had an Implant That Survived 3 Years After Implant Placement — 3; 6; 7 participants
Phase 2 N=20 Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study
Carcinoma, Basal Cell
Primary: Change in Occurence of Local Skin Reaction (LSR) Side Effects TOTAL COMPOSITE SCORE — 7; 9; 4; 2 score on a scale